How effective is Cellcept for Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 2.9/5 Long term ratings: 5/5
This is a phase IV clinical study of how effective Cellcept (mycophenolate mofetil) is for Multiple sclerosis and for what kind of people. The study is created by eHealthMe from 7 Cellcept users and is updated continuously.
What is Cellcept?
Cellcept has active ingredients of mycophenolate mofetil. It is often used in systemic lupus erythematosus. eHealthMe is studying from 41,872 Cellcept users. Check the latest studies of Cellcept.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,111 drugs and 1,354 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
7 people are studied for taking Cellcept in Multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Cellcept effectiveness for Multiple sclerosis (number of people):
Overall:
- not at all: 2
- somewhat: 1
- moderate: 2
- high: 0
- very high: 2
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 0
- high: 0
- very high: 2
Gender of people who take Cellcept for Multiple sclerosis *:
- female: 71.43 %
- male: 28.57 %
Age of people who take Cellcept for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 28.57 %
- 40-49: 28.57 %
- 50-59: 42.86 %
- 60+: 0.0 %
Who find Cellcept more effective for Multiple Sclerosis?
Gender of people who take Cellcept for Multiple sclerosis *:
- female: 50 %
- male: 50 %
Age of people who take Cellcept for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 50 %
- 40-49: 50 %
- 50-59: 0.0 %
- 60+: 0.0 %
* Approximation only. Some reports may have incomplete information.
Do you take Cellcept?
- You can start a phase IV clinical trial to monitor Cellcept safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Cellcept (41,872 reports)
Treatments, associated drugs and conditions:
- Multiple sclerosis (799,632 reports)
How the study uses the data?
The study is based on mycophenolate mofetil (the active ingredients of Cellcept) and Cellcept (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Acetaminophen and Pentacarinat drug interactions for women aged 60+ - 4 seconds ago
- Accutane and Crohn'S Disease Aggravated for Women aged 40-49 - 7 seconds ago
- Risedronate Sodium and Celebrex drug interactions for women aged 60+ - 10 seconds ago
- Drug interactions of Flexeril and Linezolid - 10 seconds ago
- Divalproex and Seroquel drug interactions for men aged 50-59 - 10 seconds ago
- Nifedipine and Welts for Women aged 60+ - 11 seconds ago
- Nifedipine and Angioneurotic Edema for Women aged 60+ - 11 seconds ago
- Nifedipine and Angioedema for Women aged 60+ - 11 seconds ago
- Famotidine and Kidney Stones for Men aged 60+ - 14 seconds ago
- Famotidine and Stones - Kidney for Men aged 60+ - 14 seconds ago